Back to Search Start Over

Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE trial and meta-analysis

Authors :
Zhou, Z ; https://orcid.org/0000-0001-6543-7113
Jardine, MJ ; https://orcid.org/0000-0002-0160-2375
Li, Q ; https://orcid.org/0000-0002-4384-8226
Neuen, BL ; https://orcid.org/0000-0001-9276-8380
Cannon, CP
De Zeeuw, D
Edwards, R
Levin, A
Mahaffey, KW
Perkovic, V ; https://orcid.org/0000-0002-4257-7620
Neal, B ; https://orcid.org/0000-0002-0490-7465
Lindley, RI
Guerrero, RAA
Aizenberg, D
Albisu, JP
Alvarisqueta, A
Bartolacci, I
Berli, MA
Bordonava, A
Calella, P
Cantero, MC
Cartasegna, LR
Cercos, E
Coloma, GC
Colombo, H
Commendatore, V
Cuadrado, J
Cuneo, CA
Cusumano, AM
Douthat, WG
Dran, RD
Farias, E
Fernandez, MF
Finkelstein, H
Fragale, G
Fretes, JO
Garcia, NH
Gastaldi, A
Gelersztein, E
Glenny, JA
Gonzalez, JP
Del Carmen Gonzalez Colaso, P
Goycoa, C
Greloni, GC
Guinsburg, A
Hermida, S
Juncos, LI
Klyver, MI
Kraft, F
Krynski, F
Lanchiotti, PV
De La Fuente, RAL
Marchetta, N
Mele, P
Nicolai, S
Novoa, PA
Orio, SI
Otreras, F
Oviedo, A
Raffaele, P
Resk, JH
Rista, L
Papini, NR
Sala, J
Santos, JC
Schiavi, LB
Sessa, H
Casabella, TS
Ulla, MR
Valdez, M
Vallejos, A
Villarino, A
Visco, VE
Wassermann, A
Zaidman, CJ
Cheung, NW
Droste, C
Fraser, I
Johnson, D
Mah, PM
Nicholls, K
Packham, D
Proietto, J
Roberts, A
Roger, S
Tsang, V
Raduan, RA
Da Costa, FAA
Amodeo, C
Turatti, LAA
Bregman, R
Sanches, FCC
Canani, LH
Chacra, AR
Borges, JLC
Vêncio, SAC
Da Silva Franco, RJ
D'Avila, D
De Souza Portes, E
De Souza, P
Phillips, Andrea
Zhou, Z ; https://orcid.org/0000-0001-6543-7113
Jardine, MJ ; https://orcid.org/0000-0002-0160-2375
Li, Q ; https://orcid.org/0000-0002-4384-8226
Neuen, BL ; https://orcid.org/0000-0001-9276-8380
Cannon, CP
De Zeeuw, D
Edwards, R
Levin, A
Mahaffey, KW
Perkovic, V ; https://orcid.org/0000-0002-4257-7620
Neal, B ; https://orcid.org/0000-0002-0490-7465
Lindley, RI
Guerrero, RAA
Aizenberg, D
Albisu, JP
Alvarisqueta, A
Bartolacci, I
Berli, MA
Bordonava, A
Calella, P
Cantero, MC
Cartasegna, LR
Cercos, E
Coloma, GC
Colombo, H
Commendatore, V
Cuadrado, J
Cuneo, CA
Cusumano, AM
Douthat, WG
Dran, RD
Farias, E
Fernandez, MF
Finkelstein, H
Fragale, G
Fretes, JO
Garcia, NH
Gastaldi, A
Gelersztein, E
Glenny, JA
Gonzalez, JP
Del Carmen Gonzalez Colaso, P
Goycoa, C
Greloni, GC
Guinsburg, A
Hermida, S
Juncos, LI
Klyver, MI
Kraft, F
Krynski, F
Lanchiotti, PV
De La Fuente, RAL
Marchetta, N
Mele, P
Nicolai, S
Novoa, PA
Orio, SI
Otreras, F
Oviedo, A
Raffaele, P
Resk, JH
Rista, L
Papini, NR
Sala, J
Santos, JC
Schiavi, LB
Sessa, H
Casabella, TS
Ulla, MR
Valdez, M
Vallejos, A
Villarino, A
Visco, VE
Wassermann, A
Zaidman, CJ
Cheung, NW
Droste, C
Fraser, I
Johnson, D
Mah, PM
Nicholls, K
Packham, D
Proietto, J
Roberts, A
Roger, S
Tsang, V
Raduan, RA
Da Costa, FAA
Amodeo, C
Turatti, LAA
Bregman, R
Sanches, FCC
Canani, LH
Chacra, AR
Borges, JLC
Vêncio, SAC
Da Silva Franco, RJ
D'Avila, D
De Souza Portes, E
De Souza, P
Phillips, Andrea
Source :
urn:ISSN:0039-2499; urn:ISSN:1524-4628; Stroke, 52, 5, 1545-1556
Publication Year :
2021

Abstract

BACKGROUND AND PURPOSE: Chronic kidney disease with reduced estimated glomerular filtration rate or elevated albuminuria increases risk for ischemic and hemorrhagic stroke. This study assessed the effects of sodium glucose cotransporter 2 inhibitors (SGLT2i) on stroke and atrial fibrillation/flutter (AF/AFL) from CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) and a meta-Analysis of large cardiovascular outcome trials (CVOTs) of SGLT2i in type 2 diabetes mellitus. METHODS: CREDENCE randomized 4401 participants with type 2 diabetes mellitus and chronic kidney disease to canagliflozin or placebo. Post hoc, we estimated effects on fatal or nonfatal stroke, stroke subtypes, and intermediate markers of stroke risk including AF/AFL. Stroke and AF/AFL data from 3 other completed large CVOTs and CREDENCE were pooled using random-effects meta-Analysis. RESULTS: In CREDENCE, 142 participants experienced a stroke during follow-up (10.9/1000 patient-years with canagliflozin, 14.2/1000 patient-years with placebo; hazard ratio [HR], 0.77 [95% CI, 0.55-1.08]). Effects by stroke subtypes were: ischemic (HR, 0.88 [95% CI, 0.61-1.28]; n=111), hemorrhagic (HR, 0.50 [95% CI, 0.19-1.32]; n=18), and undetermined (HR, 0.54 [95% CI, 0.20-1.46]; n=17). There was no clear effect on AF/AFL (HR, 0.76 [95% CI, 0.53-1.10]; n=115). The overall effects in the 4 CVOTs combined were: Total stroke (HRpooled, 0.96 [95% CI, 0.82-1.12]), ischemic stroke (HRpooled, 1.01 [95% CI, 0.89-1.14]), hemorrhagic stroke (HRpooled, 0.50 [95% CI, 0.30-0.83]), undetermined stroke (HRpooled, 0.86 [95% CI, 0.49-1.51]), and AF/AFL (HRpooled, 0.81 [95% CI, 0.71-0.93]). There was evidence that SGLT2i effects on total stroke varied by baseline estimated glomerular filtration rate (P=0.01), with protection in the lowest estimated glomerular filtration rate (45 mL/min/1.73 m2]) subgroup (HRpooled, 0.50 [95% CI, 0.31-0.79]). CONCLUSIONS: Although we found no clear effect

Details

Database :
OAIster
Journal :
urn:ISSN:0039-2499; urn:ISSN:1524-4628; Stroke, 52, 5, 1545-1556
Notes :
application/pdf
Publication Type :
Electronic Resource
Accession number :
edsoai.on1259603886
Document Type :
Electronic Resource